Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jaeger U, Hildebrandt M, Hudecek M, Kersten MJ, Koehl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua AU, Chen D, Vrhovac R, Gribben JG, Kroeger N, Einsele H, Yakoub-Agha (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 33

Pages Range: 259-275

Journal Issue: 3

DOI: 10.1016/j.annonc.2021.12.003

Abstract

Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future. Design: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field. Results: Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues. Conclusions: We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.

Involved external institutions

St. James's Hospital Ireland (IE) University College London (UCL) United Kingdom (GB) Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu Poland (PL) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) Italy (IT) Aix-Marseille University / Aix-Marseille Université France (FR) Università Vita-Salute San Raffaele (UniSR) Italy (IT) Universitätsklinikum Regensburg Germany (DE) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust United Kingdom (GB) University of Salamanca / Universidad de Salamanca Spain (ES) Medizinische Universität Wien Austria (AT) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Universitätsklinikum Würzburg Germany (DE) University of Amsterdam Netherlands (NL) Universität Leipzig Germany (DE) University Medical Centre Utrecht (UMC Utrecht) Netherlands (NL) Karolinska Institute Sweden (SE) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne France (FR) Christie NHS Foundation Trust United Kingdom (GB) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) University College London Hospitals (UCLH) United Kingdom (GB) Hospices Civils de Lyon (CHU) France (FR) Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi Italy (IT) Sheffield Teaching Hospitals NHS Foundation Trust United Kingdom (GB) Nicolaus Copernicus University (NCU) / Uniwersytet Mikołaja Kopernika w Toruniu (UMK) Poland (PL) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Université de Paris France (FR) Hospital Clínic de Barcelona Spain (ES) Zagreb University Hospital Centre / Klinički bolnički centar Zagreb (KBC) Croatia (HR) Queen Mary, University of London United Kingdom (GB) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) LILLE 1 University - Science and Technology France (FR) Goethe-Universität Frankfurt am Main Germany (DE)

How to cite

APA:

Hayden, P.J., Roddie, C., Bader, P., Basak, G.W., Bonig, H., Bonini, C.,... Yakoub-Agha, . (2022). Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 33(3), 259-275. https://dx.doi.org/10.1016/j.annonc.2021.12.003

MLA:

Hayden, P. J., et al. "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)." Annals of Oncology 33.3 (2022): 259-275.

BibTeX: Download